semaglutide fda changes just got FDA-approved for kidney disease. This everything., January 2025. The approved semaglutide (Ozempic/Wegovy) for a new indication: reducing kidney disease progression in Maximizing Semaglutide: Understanding the Doses

The effects of TAs on lipid metabolism were associated with activation of the hepatic farnesoid X receptor (FXR) pathway, involving peroxisome proliferator-activated receptor alpha (PPAR) and sterol regulatory element-binding protein 1 (SREBP-1)

The high heterogeneity in terms of type of coffee, doses and duration of the studies, the lack of information on coffee and/or brew bioactive composition, as well as the choice of biomarkers and the methods used for their evaluation, may partially explain the variability observed among findings

Neurochem Int 29:145152 Sekhon B, Sekhon C, Khan M, Patel SJ, Singh I, Singh AK (2003) N -acetyl cysteine protects against injury in a rat model of focal cerebral ischemia

A 2024 study presented at the American Association of Clinical Endocrinology meeting showed that combining androgen receptor modulators with GLP-1 therapy increased lean mass while simultaneously decreasing fat mass

Document your baseline